News - Cardio-vascular, Respiratory and Pulmonary


Popular Filters

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline


Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Pharmacovigilance Risk Assessment Committee April meeting highlights

Pharmacovigilance Risk Assessment Committee April meeting highlights


The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) gave a recommendation…

Cardio-vascularEuropeMen's HealthNeurologicalPharmaceuticalRegulationRespiratory and Pulmonary

MedImmune joins research collaboration with the University of California

MedImmune joins research collaboration with the University of California


MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

Antibiotics and Infectious diseasesCardio-vascularInflammatory diseasesMedImmuneMetabolicsNeurologicalOncologyPharmaceuticalResearchRespiratory and PulmonaryUSA

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company


‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal…

AstraZenecaBrilintaCardio-vascularCrestorDiabetesExenatide InjectionFinancialInterviewsNexiumOncologyPharmaceuticalRespiratory and PulmonarySymbicortUK

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed

EMA/CHMP gives Novartis positive opinion for Xolair; negative opinion on RLX030 to be appealed


The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given…

Cardio-vascularEuropeNovartisPharmaceuticalRegulationRespiratory and PulmonaryXolair

Forest Laboratories announces new appointments to its executive team


New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates


The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

Further highlights from European Society of Cardiology meeting


The ongoing European Society of Cardiology meeting in Amsterdam, Netherlands, continues to produce both…

ActelionalogliptinAmgenBiotechnologyCardio-vascularCytokineticsDiabetesomecamtiv mecarbilOpsumitPharmaceuticalResearchRespiratory and PulmonaryTakeda Pharmaceuticals

Akrikhin expands deal with Merck & Co


Leading Russian drugmaker Akrikhin says it has expanded its partnership with US pharma giant Merck &…

Akrikhin PharmaceuticalsCardio-vascularDiabetesEuropeEzetrolJanumetJanuviaMarkets & MarketingMerck & CoNoxafilPharmaceuticalProductionRespiratory and PulmonarySingulair

Merck & Co opens new $120 million manufacturing plant in China


US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Japanese approvals for Eylea, Tresiba, Seebri and Aimix


There was a flurry of announcements from Japan's Ministry of Health, Labor and Welfare (MHLW) on Friday,…

AimixAsia-PacificBayerCardio-vascularDainippon Sumitomo PharmaDiabetesEyleaNovartisNovo NordiskOphthalmicsPharmaceuticalRegeneronRegulationRespiratory and PulmonarySeebri BreezhalerShionogiTresibaVectura

Unigene and Tarix report highly increased oral bioavailability of "Peptelligence-engineered" TXA127


USA-based Unigene Laboratories Laboratories (OTCBB: UGNE) and Tarix Pharmaceuticals yesterday announced…

Cardio-vascularLicensingPharmaceuticalResearchRespiratory and PulmonaryTarix PharmaceuticalsTXA127Unigene Labs

NICE now backs Xarelto to treat blood clots; negative on Bronchitol for CF


In final draft guidance published today (1 June 1), UK drugs watchdog the National Institute for Health…

BayerBronchitolCardio-vascularEuropePharmaceuticalPharmaxisPricingRare diseasesRegulationRespiratory and PulmonaryXarelto

Strong results for Bayer's Xarelto in treating pulmonary blood clots


German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

B-MS ties knot with Duke University on R&D


Bristol-Myers Squibb has forged a partnership with Duke University in the USA that will see the academic…

Bristol-Myers SquibbCardio-vascularGeneralHomeLysophosphatidic acid 1 (LPA1)MetabolicsOncologyPfizerPharmaceuticalRespiratory and PulmonarySanofi

NICE publishes final technology appraisal guidance for four conditions


The UK’s drugs watch dog the National Institute for Health and Clinical Excellence (NICE) has today…

AvastinCardio-vascularDaxasEliquisErbituxEuropeOncologyPharmaceuticalPricingRegulationRespiratory and PulmonaryRituxanVectibix

Adeona Pharma and Intrexon collaborate for synthetic DNA-based PAH therapy


USA-based Adeona Pharmaceuticals (NYSE Amex: AEN) and the Human Therapeutics Division of Intrexon Corp…

Adeona PharmaCardio-vascularIntrexonLicensingPharmaceuticalResearchRespiratory and Pulmonary

Longer-term safety profile of InterMune’s Esbriet in IPF demonstrated; Call for greater awareness of PF


US biotech firm InterMune (Nasdaq: ITMN) has reported that new data at the European Respiratory Society…

BiotechnologyCardio-vascularEsbrietHealthcareInterMunePharmaceuticalResearchRespiratory and Pulmonary

Novartis cancer drug imatinib shows efficacy in PAH


Swiss drug major Novartis (NOVN: VX) yesterday announced new data today at the European Respiratory Society…

ActelionCardio-vascularImatinib MesylateNovartisPharmaceuticalResearchRespiratory and PulmonaryTracleer

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top